Index
RUT
Market Cap
2.06B
Enterprise Value
1.99B
Income
24.22M
Sales
306.30M
Book/sh
7.23
Cash/sh
3.17
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
0.00%
Employees
398
IPO
Feb 04, 1997
P/E
87.11
Forward P/E
46.48
PEG
0.76
P/S
6.73
P/B
5.57
P/C
12.69
P/FCF
33.43
EV/EBITDA
64.00
EV/Sales
6.51
Quick Ratio
4.69
Current Ratio
5.04
Debt/Eq
0.26
LT Debt/Eq
0.22
Option/Short
Yes / Yes
EPS (ttm)
0.46
EPS next Y
0.87
EPS next Q
0.06
EPS this Y
67.19%
EPS next Y
61.92%
EPS next 5Y
61.01%
EPS past 3/5Y
- 39.20%
Sales past 3/5Y
18.90% 17.34%
EPS Y/Y TTM
228.76%
Sales Y/Y TTM
22.95%
EPS Q/Q
483.64%
Sales Q/Q
22.48%
Insider Own
1.19%
Insider Trans
-15.35%
Inst Own
108.15%
Inst Trans
-2.29%
ROA
5.16%
ROE
7.16%
ROIC
5.38%
Gross Margin
74.56%
Oper. Margin
5.95%
Profit Margin
7.91%
SMA20
-2.08%
SMA50
-0.79%
SMA200
4.17%
Trades
Shs Outstand
51.17M
Shs Float
50.60M
52W High
49.32 -18.37%
52W Low
28.95 39.07%
Volatility
4.02% 3.64%
ATR (14)
1.62
RSI (14)
46.16
Beta
1.09
Rel Volume
1.15
Avg Volume
519.33K
Volume
598,773
Perf Week
-5.34%
Perf Month
2.08%
Perf Quarter
-12.57%
Perf Half Y
13.19%
Perf YTD
11.80%
Perf Year
16.59%
Perf 3Y
17.10%
Perf 5Y
-12.52%
Perf 10Y
1613.19%
Prev Close
42.91
Price
40.26
Change %
-6.18%
Analysts 10 incl. previous ratings
Rating Distribution 7 Buy · 3 Hold · 0 Sell
Date Action Analyst Rating Change Price Target Change Implied Upside Sep 17, 2025 Downgrade B
Buy → Neutral Aug 09, 2024 Initiated C
Buy $57 +41.6% Jun 20, 2024 Initiated T TD Cowen
Buy $55 +36.6% Jan 25, 2024 Upgrade T Truist
Hold → Buy $39 → $51 +26.7% Aug 08, 2023 Upgrade B
Neutral → Buy $39 -3.1% Nov 10, 2022 Downgrade B
Buy → Neutral Nov 09, 2022 Downgrade T Truist
Buy → Hold Oct 14, 2022 Resumed S
Overweight $40 -0.6% Jan 11, 2021 Downgrade O Oppenheimer
Outperform → Perform Dec 18, 2020 Initiated S
Overweight $31 -23.0% Sep 17, 2020 Initiated T Truist
Buy $24 -40.4% Oct 09, 2019 Initiated H
Buy $19 -52.8% Feb 28, 2019 Downgrade N
Buy → Hold Aug 08, 2018 Reiterated N
Buy $15 → $14 -65.2% Jul 16, 2018 Upgrade L
Neutral → Buy Apr 04, 2018 Initiated L
Outperform $15 -62.7% Mar 06, 2018 Reiterated N
Buy $5 → $15 -62.7% Mar 06, 2018 Downgrade L
Buy → Neutral Mar 05, 2018 Reiterated B
Buy $8 → $13 -67.7% Jun 21, 2017 Initiated B
Buy $6 -85.1%
Oct-28-26 05:06PM
(Earnings Whispers)
-5.04%
Oct-22-26 08:30AM
Sep-22-26 08:09AM
Sep-08-26 08:30AM
Aug-03-26 10:55AM
07:55AM
Loading…
Jul-30-26 07:55AM
Jul-16-26 08:32AM
08:30AM
Jul-02-26 08:48AM
Jun-09-26 08:30AM
May-07-26 07:45AM
Apr-23-26 08:30AM
Apr-02-26 02:40PM
Mar-09-26 08:31PM
Mar-04-26 08:00AM
08:30AM
Loading…
Mar-03-26 08:30AM
Feb-28-26 08:05PM
Feb-27-26 12:39PM
Feb-26-26 04:11PM
12:15PM
07:55AM
Feb-12-26 08:30AM
Jan-13-26 12:57PM
09:00AM
Jan-06-26 08:30AM
Dec-21-25 09:57AM
Nov-14-25 08:30AM
Nov-10-25 09:55AM
Nov-06-25 04:01PM
09:10AM
07:55AM
Loading…
07:55AM
Oct-31-25 09:15AM
Oct-23-25 08:30AM
Oct-22-25 08:48AM
Oct-20-25 11:08PM
Sep-12-25 08:53AM
Sep-11-25 03:46PM
Aug-28-25 08:30AM
Aug-20-25 12:13AM
Jul-31-25 09:15AM
08:08AM
Jul-30-25 09:44AM
09:00AM
Jul-24-25 09:47AM
Jul-17-25 08:30AM
Jun-10-25 08:30AM
May-09-25 03:13AM
May-08-25 09:05AM
08:45AM
07:55AM
May-07-25 02:18PM
10:08AM
08:30AM
May-06-25 05:35PM
May-01-25 05:15PM
Apr-30-25 08:39AM
Apr-24-25 08:30AM
Mar-04-25 08:30AM
Feb-28-25 02:11AM
01:51AM
(Thomson Reuters StreetEvents)
Feb-27-25 09:05AM
07:54AM
Feb-26-25 07:28AM
Feb-13-25 08:30AM
Jan-14-25 04:05PM
Jan-08-25 08:30AM
Dec-19-24 07:36AM
Nov-11-24 02:06PM
(Investor's Business Daily)
+5.15%
Nov-08-24 04:03AM
Nov-07-24 09:10AM
07:55AM
Nov-06-24 07:15AM
Oct-24-24 08:30AM
Oct-22-24 09:31AM
Oct-18-24 03:04PM
Oct-09-24 03:44PM
Aug-29-24 09:17AM
Aug-26-24 07:45AM
Aug-16-24 10:33AM
Aug-15-24 04:05PM
Aug-07-24 08:30AM
Aug-05-24 12:00PM
Aug-01-24 09:05AM
07:55AM
Jul-29-24 03:45PM
Jul-22-24 08:30AM
Jul-18-24 08:30AM
Jul-16-24 07:01PM
Jul-02-24 09:58AM
Jun-27-24 02:03PM
Jun-25-24 07:22AM
Jun-20-24 09:54AM
Jun-11-24 08:30AM
May-22-24 08:30AM
May-21-24 06:42AM
May-09-24 03:28PM
03:08AM
May-08-24 11:24PM
(Thomson Reuters StreetEvents)
09:35AM
09:10AM
Show Previous News
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
MCLAUGHLIN KEVIN F Director Aug 12 '26 Option Exercise 13.05 7,000 91,350 25,300 Aug 14 04:05 PM MCLAUGHLIN KEVIN F Director Aug 12 '26 Sale 44.53 7,000 311,710 18,300 Aug 14 04:05 PM MCLAUGHLIN KEVIN F Director Aug 12 '26 Proposed Sale 44.11 7,000 308,770 Aug 12 09:47 AM Halpin Michael Chief Operating Officer Aug 03 '26 Option Exercise 16.66 10,000 166,600 26,394 Aug 05 04:05 PM Halpin Michael Chief Operating Officer Aug 03 '26 Sale 46.84 10,000 468,400 16,394 Aug 05 04:05 PM Halpin Michael Officer Aug 03 '26 Proposed Sale 45.98 10,000 459,800 Aug 03 12:43 PM SIEGAL JONATHAN Principal Accounting Officer Jul 30 '26 Option Exercise 31.51 4,500 141,810 3,578 Jul 31 04:05 PM SIEGAL JONATHAN Principal Accounting Officer Jul 30 '26 Sale 48.90 4,500 220,050 1,078 Jul 31 04:05 PM SIEGAL JONATHAN Officer Jul 30 '26 Proposed Sale 48.90 4,500 220,050 Jul 30 10:56 AM SIEGAL JONATHAN Principal Accounting Officer Jun 26 '26 Option Exercise 29.82 2,500 74,550 3,386 Jun 30 04:05 PM SIEGAL JONATHAN Principal Accounting Officer Jun 26 '26 Sale 44.90 2,732 122,667 886 Jun 30 04:05 PM Mara Joseph Anthony Jr Chief Financial Officer Jun 26 '26 Sale 44.75 5,000 223,750 16,009 Jun 30 04:05 PM Hopper Jonathan Mark Chief Medical Officer Jun 26 '26 Option Exercise 29.82 10,000 298,200 80,753 Jun 30 04:05 PM Hopper Jonathan Mark Chief Medical Officer Jun 26 '26 Sale 45.00 10,000 450,000 75,753 Jun 30 04:05 PM Flynn Sean C. Chief Legal Officer Jun 26 '26 Option Exercise 16.25 15,000 243,750 16,647 Jun 30 04:05 PM Flynn Sean C. Chief Legal Officer Jun 26 '26 Sale 45.64 15,000 684,600 1,647 Jun 30 04:05 PM Flynn Sean C. Officer Jun 26 '26 Proposed Sale 45.64 15,000 684,659 Jun 26 04:21 PM Mara Joseph Anthony Jr Officer Jun 26 '26 Proposed Sale 44.75 5,000 223,750 Jun 26 04:12 PM SIEGAL JONATHAN Officer Jun 26 '26 Proposed Sale 44.90 2,732 122,667 Jun 26 04:02 PM Hopper Jonathan Mark Officer Jun 26 '26 Proposed Sale 45.00 10,000 450,000 Jun 26 03:55 PM Halpin Michael Chief Operating Officer Jun 18 '26 Option Exercise 16.66 10,000 166,600 26,248 Jun 22 04:05 PM Halpin Michael Chief Operating Officer Jun 18 '26 Sale 40.24 10,000 402,400 16,248 Jun 22 04:05 PM Flynn Sean C. Chief Legal Officer Jun 18 '26 Option Exercise 16.25 15,000 243,750 16,647 Jun 22 04:05 PM Flynn Sean C. Chief Legal Officer Jun 18 '26 Sale 40.21 15,000 603,150 1,647 Jun 22 04:05 PM Flynn Sean C. Officer Jun 18 '26 Proposed Sale 40.21 15,000 603,148 Jun 18 04:26 PM Halpin Michael Officer Jun 18 '26 Proposed Sale 40.24 10,000 402,401 Jun 18 04:11 PM Hopper Jonathan Mark Chief Medical Officer Jun 02 '26 Option Exercise 16.66 4,375 72,888 80,128 Jun 04 04:05 PM Hopper Jonathan Mark Chief Medical Officer Jun 02 '26 Sale 35.00 4,375 153,125 75,753 Jun 04 04:05 PM Hopper Jonathan Mark Officer Jun 02 '26 Proposed Sale 35.00 4,375 153,125 Jun 02 02:40 PM MCLAUGHLIN KEVIN F Director May 13 '26 Option Exercise 7.84 7,000 54,880 21,800 May 15 04:06 PM MCLAUGHLIN KEVIN F Director May 13 '26 Sale 32.83 7,000 229,775 18,300 May 15 04:06 PM Wotton Paul K Director May 11 '26 Sale 32.74 10,000 327,425 18,802 May 13 04:05 PM MCLAUGHLIN KEVIN F Director May 13 '26 Proposed Sale 32.57 7,000 227,990 May 13 02:16 PM Wotton Paul K Director May 11 '26 Proposed Sale 32.74 10,000 327,425 May 11 02:32 PM Mara Joseph Anthony Jr Chief Financial Officer May 07 '26 Sale 40.50 5,000 202,500 21,009 May 08 04:05 PM SIEGAL JONATHAN Principal Accounting Officer May 06 '26 Sale 38.00 3,433 130,454 2,540 May 08 04:05 PM SIEGAL JONATHAN Principal Accounting Officer May 07 '26 Sale 40.50 1,422 57,591 1,118 May 08 04:05 PM SIEGAL JONATHAN Officer May 07 '26 Proposed Sale 40.50 1,422 57,591 May 07 12:36 PM Mara Joseph Anthony Jr Officer May 07 '26 Proposed Sale 40.50 5,000 202,500 May 07 12:02 PM SIEGAL JONATHAN Officer May 06 '26 Proposed Sale 38.00 3,433 130,454 May 06 03:30 PM Hopper Jonathan Mark Chief Medical Officer Apr 02 '26 Option Exercise 10.95 3,472 38,018 79,028 Apr 06 04:05 PM Hopper Jonathan Mark Chief Medical Officer Apr 02 '26 Sale 35.00 3,472 121,520 75,556 Apr 06 04:05 PM Hopper Jonathan Mark Officer Apr 02 '26 Proposed Sale 35.00 3,472 121,520 Apr 02 02:28 PM Rubino Alan L Director Mar 25 '26 Option Exercise 2.76 15,000 41,400 60,994 Mar 27 04:05 PM Hagen Heidi Director Mar 23 '26 Option Exercise 2.76 15,000 41,400 46,850 Mar 25 04:05 PM Hagen Heidi Director Mar 23 '26 Sale 32.41 15,000 486,150 31,850 Mar 25 04:05 PM Hagen Heidi Director Mar 23 '26 Proposed Sale 32.41 15,000 486,163 Mar 23 04:08 PM Flynn Sean C. Chief Legal Officer Mar 02 '26 Option Exercise 16.25 15,000 243,750 16,262 Mar 04 04:05 PM Flynn Sean C. Chief Legal Officer Mar 02 '26 Sale 35.18 21,421 753,530 1,262 Mar 04 04:05 PM Halpin Michael Chief Operating Officer Mar 02 '26 Sale 35.30 10,305 363,766 16,080 Mar 04 04:05 PM Flynn Sean C. Officer Mar 02 '26 Proposed Sale 35.18 21,421 753,509 Mar 02 04:54 PM Halpin Michael Officer Mar 02 '26 Proposed Sale 35.30 10,305 363,749 Mar 02 04:21 PM Colangelo Dominick President and CEO Feb 24 '26 Option Exercise 0.00 18,250 0 321,270 Feb 26 04:05 PM Hopper Jonathan Mark Chief Medical Officer Feb 24 '26 Option Exercise 0.00 4,650 0 76,192 Feb 26 04:05 PM SIEGAL JONATHAN Principal Accounting Officer Feb 24 '26 Option Exercise 0.00 3,415 0 6,585 Feb 26 04:05 PM Mara Joseph Anthony Jr Chief Financial Officer Feb 24 '26 Option Exercise 0.00 9,250 0 27,262 Feb 26 04:05 PM Halpin Michael Chief Operating Officer Feb 24 '26 Option Exercise 0.00 10,500 0 28,871 Feb 26 04:05 PM Flynn Sean C. Chief Legal Officer Feb 24 '26 Option Exercise 0.00 6,500 0 9,014 Feb 26 04:05 PM Colangelo Dominick President and CEO Feb 18 '26 Option Exercise 0.00 11,700 0 290,427 Feb 20 04:06 PM Flynn Sean C. Chief Legal Officer Feb 18 '26 Option Exercise 0.00 5,325 0 5,097 Feb 20 04:06 PM Hopper Jonathan Mark Chief Medical Officer Feb 18 '26 Option Exercise 0.00 2,325 0 72,009 Feb 20 04:06 PM Mara Joseph Anthony Jr Chief Financial Officer Feb 18 '26 Option Exercise 0.00 7,380 0 20,179 Feb 20 04:06 PM SIEGAL JONATHAN Principal Accounting Officer Feb 18 '26 Option Exercise 0.00 2,920 0 4,682 Feb 20 04:06 PM Halpin Michael Chief Operating Officer Feb 18 '26 Option Exercise 0.00 9,075 0 22,669 Feb 20 04:06 PM MCLAUGHLIN KEVIN F Director Feb 11 '26 Option Exercise 2.63 7,000 18,410 22,100 Feb 13 04:05 PM MCLAUGHLIN KEVIN F Director Feb 11 '26 Sale 34.66 7,000 242,620 15,100 Feb 13 04:05 PM MCLAUGHLIN KEVIN F Director Feb 11 '26 Proposed Sale 35.62 7,000 249,340 Feb 11 10:07 AM Halpin Michael Chief Operating Officer Jan 07 '26 Option Exercise 16.66 10,000 166,600 26,080 Jan 09 04:05 PM Halpin Michael Chief Operating Officer Jan 07 '26 Sale 40.48 10,000 404,800 16,080 Jan 09 04:05 PM Halpin Michael Officer Jan 07 '26 Proposed Sale 40.48 10,000 404,833 Jan 07 04:22 PM Hopper Jonathan Mark Chief Medical Officer Dec 02 '25 Option Exercise 18.00 1,652 29,736 68,214 Dec 04 04:05 PM Hopper Jonathan Mark Chief Medical Officer Dec 02 '25 Sale 39.14 1,652 64,659 66,562 Dec 04 04:05 PM Wotton Paul K Director Dec 02 '25 Sale 37.97 2,500 94,925 28,102 Dec 04 04:05 PM Wotton Paul K Director Dec 03 '25 Sale 37.83 2,500 94,575 25,602 Dec 04 04:05 PM Wotton Paul K Director Dec 03 '25 Proposed Sale 37.83 2,500 94,575 Dec 03 11:25 AM Wotton Paul K Director Dec 02 '25 Proposed Sale 37.97 2,500 94,919 Dec 02 04:08 PM Hopper Jonathan Mark Officer Dec 02 '25 Proposed Sale 39.14 1,652 64,659 Dec 02 10:10 AM Halpin Michael Chief Operating Officer Nov 11 '25 Option Exercise 16.66 2,642 44,016 18,574 Nov 13 04:05 PM Halpin Michael Chief Operating Officer Nov 11 '25 Sale 40.41 2,642 106,763 15,932 Nov 13 04:05 PM MCLAUGHLIN KEVIN F Director Nov 10 '25 Option Exercise 2.63 7,000 18,410 22,100 Nov 12 04:06 PM MCLAUGHLIN KEVIN F Director Nov 10 '25 Sale 38.59 7,000 270,130 15,100 Nov 12 04:06 PM Halpin Michael Officer Nov 11 '25 Proposed Sale 40.41 2,642 106,760 Nov 12 07:33 AM Halpin Michael Chief Operating Officer Nov 06 '25 Option Exercise 16.66 7,358 122,584 23,290 Nov 10 04:05 PM Halpin Michael Chief Operating Officer Nov 06 '25 Sale 40.47 7,358 297,778 15,932 Nov 10 04:05 PM MCLAUGHLIN KEVIN F Director Nov 10 '25 Proposed Sale 39.71 7,000 277,970 Nov 10 02:47 PM Halpin Michael Officer Nov 06 '25 Proposed Sale 40.47 7,358 297,775 Nov 06 04:19 PM
Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.
CEO Mr. Dominick C. Colangelo Esq.
CFO & Treasurer Mr. Joseph Anthony Mara Jr.
Chief Operating Officer Mr. Michael Halpin
Chief Legal Officer Mr. Sean C. Flynn
M.B. Ch.B. Dr. Jonathan M. Hopper FRCSEd.
V